SIGA Technologies (NASDAQ: SIGA) and Anavex Life Sciences Corp. (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares SIGA Technologies and Anavex Life Sciences Corp.’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
SIGA Technologies $21.28 million 7.69 -$18.34 million N/A N/A
Anavex Life Sciences Corp. N/A N/A -$15.61 million ($0.39) -11.95

Anavex Life Sciences Corp. has higher revenue, but lower earnings than SIGA Technologies.

Insider & Institutional Ownership

24.4% of Anavex Life Sciences Corp. shares are held by institutional investors. 11.6% of Anavex Life Sciences Corp. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares SIGA Technologies and Anavex Life Sciences Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SIGA Technologies -175.90% N/A -18.99%
Anavex Life Sciences Corp. N/A -95.68% -84.88%

Analyst Ratings

This is a breakdown of recent recommendations for SIGA Technologies and Anavex Life Sciences Corp., as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SIGA Technologies 0 0 0 0 N/A
Anavex Life Sciences Corp. 0 0 3 0 3.00

Anavex Life Sciences Corp. has a consensus target price of $13.67, indicating a potential upside of 193.28%. Given Anavex Life Sciences Corp.’s higher possible upside, analysts plainly believe Anavex Life Sciences Corp. is more favorable than SIGA Technologies.

Summary

Anavex Life Sciences Corp. beats SIGA Technologies on 6 of the 9 factors compared between the two stocks.

About SIGA Technologies

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for SIGA Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.